A Phase 1b Study to Assess the Safety, Antiviral Efficacy and Pharmacokinetics of PPI-461 in Patients With HCV Genotype-1 Infection.
Phase of Trial: Phase I
Latest Information Update: 02 Feb 2012
At a glance
- Drugs PPI 461 (Primary)
- Indications Hepatitis C
- Focus Adverse reactions; Pharmacokinetics; Therapeutic Use
- 06 Nov 2011 Results were presented at the Annual Meeting of the American Association for the Study of Liver Diseases (AASLD).
- 02 May 2011 Actual end date (May 2011) added as reported by ClinicalTrials.gov.
- 02 May 2011 Status changed from recruiting to completed as reported by ClinicalTrials.gov.
Most Recent Events
Table of Contents
- At a glance
- Trial Overview
- Trial Details
- Trial Centres
- Trial History